Genstruct Appoints Dr. Michael Pavia to Its Board of Directors

Selventa

Genstruct Appoints Dr. Michael Pavia to Its Board of Directors

February 14, 2005

CAMBRIDGE, Mass., Feb. 14 /PRNewswire/ -- Genstruct, Inc., a knowledge-driven discovery company using systems biology to discover biomarkers to increase the effectiveness of drug discovery and development, today announced the appointment of Michael R. Pavia, Ph.D., former chief technology officer (CTO) of Millennium Pharmaceuticals, to its Board of Directors.

"Mike's extensive experience in the development and integration of new technologies into the drug discovery and development process and in-depth knowledge of the life sciences industry, as well as his enthusiastic entrepreneurism make him a great addition to our Board of Directors," said Keith O. Elliston, Ph.D., president and CEO of Genstruct. "He has an impressive track record in the pharmaceutical industry, and will assist us in growing our relationships with pharmaceutical companies, such as our current partners Pfizer and Berlex. Mike's past experience in bringing new technology to pharmaceutical companies and into the drug discovery and development process as the CTO of Millennium will provide us with insights to help us continue to build the Genstruct business."

"Genstruct's approach to systems biology is powerful and extremely innovative," said Dr. Pavia. "Genstruct's unique systems biology platform has been proven through research studies in the areas of cancer and diabetes and dyslipidemia. I look forward to helping Genstruct develop their methodology and scientific expertise to improve the processes of understanding and treating complex diseases."

Dr. Pavia is an entrepreneur-in-residence with Oxford Biosciences Partners. Prior to joining Oxford in 2002, he was CTO at Millennium Pharmaceuticals, where his major focus was improving the productivity and output of the drug discovery and development process through the appropriate integration and use of new technologies. Dr. Pavia has over 20 years of experience in pharmaceutical research and discovery. He was formerly vice president - Cambridge Research - at Sphinx Pharmaceuticals, a division of Eli Lilly & Co., focusing on the development of combinatorial chemistry technologies. Prior to Sphinx, Dr. Pavia held senior scientific positions in the Department of Chemistry at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert. He holds a B.S. in chemistry from Lehigh University and a Ph.D. in organic chemistry from the University of Pennsylvania.

About Genstruct
Founded in 2002, Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders, and inflammation. Genstruct has developed a platform for the discovery of compound mechanisms of action (MOA) and biomarkers called the Molecular Epistemics(TM) Platform. This platform comprises a suite of patent-pending technologies that model and analyze compound MOA and disease mechanisms: the Knowledge Assembly(TM) process which enables rapid, ongoing construction of addressable biological models and the Epistemics Engine(TM) System for mining and refining the models for mechanism discovery and validation. Genstruct engages in internal discovery and external development partnerships that apply the Molecular Epistemics Platform to accelerate and increase the output of drug discovery and development programs. The Company is based in Cambridge, Mass., and its investors include Flagship Ventures of Cambridge, Mass. and A. M. Pappas & Associates of Research Triangle Park, N.C. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contact
Karen Higgins
A & E Communications for Genstruct
(610) 831-5723
khiggins@aandecomm.com